| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 | FY2023 | FY2022 | FY2022 | FY2022 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Premiums | $3.50B+0.5% | $3.48B-4.3% | $3.64B-1.2% | $3.68B+8.0% | $3.41B | — | $3.68B | — | — | — |
| Net investment income | $3.13B-1.1% | $3.16B-0.7% | $3.18B+1.2% | $3.15B-6.6% | $3.37B | — | $3.15B | — | — | — |
| Net investment gains (losses) | $59.0M+353.8% | $13.0M-43.5% | $23.0M+1250.0% | -$2.0M-100.6% | $322.0M | — | -$2.0M | — | — | — |
| Policy fees and other income | $618.0M-3.7% | $642.0M-0.6% | $646.0M-3.7% | $671.0M-7.3% | $724.0M | — | $671.0M | — | — | — |
| Total revenues | $7.30B+0.1% | $7.29B-2.6% | $7.49B+309.0% | $1.83B-3.2% | $1.89B+2.0% | $1.85B-75.3% | $7.50B+305.6% | $1.85B-2.1% | $1.89B-0.3% | $1.89B |
| Benefits and other changes in policy reserves | $4.82B+1.2% | $4.77B-0.4% | $4.78B+11.2% | $4.30B-5.9% | $4.58B | — | $4.30B | — | — | — |
| Liability remeasurement (gains) losses | $313.0M+104.6% | $153.0M-73.9% | $587.0M+302.4% | -$290.0M-219.8% | $242.0M | — | -$290.0M | — | — | — |
| Changes in fair value of market risk benefits and associated hedges | $3.0M+123.1% | -$13.0M-8.3% | -$12.0M+88.5% | -$104.0M+35.0% | -$160.0M | — | -$104.0M | — | — | — |
| Interest credited | $386.0M-14.8% | $453.0M-9.9% | $503.0M-0.2% | $504.0M-1.4% | $511.0M | — | $504.0M | — | — | — |
| Acquisition and operating expenses, net of deferrals | $1.01B+3.3% | $977.0M+3.7% | $942.0M-26.7% | $1.28B+28.8% | $998.0M | — | $1.28B | — | — | — |
| Amortization of deferred acquisition costs and intangibles | $231.0M-7.2% | $249.0M-5.7% | $264.0M-19.0% | $326.0M-15.1% | $384.0M | — | $326.0M | — | — | — |
| Interest expense | $105.0M-8.7% | $115.0M-2.5% | $118.0M+11.3% | $106.0M-33.8% | $160.0M | — | $106.0M | — | — | — |
| Total benefits and expenses | $6.87B+2.5% | $6.70B-6.8% | $7.18B+312.7% | $1.74B+4.2% | $1.67B+1.6% | $1.65B-73.2% | $6.13B+276.5% | $1.63B+0.1% | $1.63B+5.9% | $1.54B |
| Income (loss) from continuing operations before income taxes | $433.0M-27.2% | $595.0M+96.4% | $303.0M-77.8% | $1.36B+22.8% | $1.11B | — | $1.36B | — | — | — |
| Provision (benefit) for income taxes | $84.0M-46.8% | $158.0M+51.9% | $104.0M-67.4% | $319.0M+28.6% | $248.0M | — | $319.0M | — | — | — |
| Income (loss) from continuing operations | $349.0M-20.1% | $437.0M+119.6% | $199.0M+231.7% | $60.0M-63.9% | $166.0M+7.8% | $154.0M-85.3% | $1.05B+530.1% | $166.0M-16.2% | $198.0M-27.2% | $272.0M |
| Income (loss) from discontinued operations, net of taxes | $1.0M+110.0% | -$10.0M | $0 | $0-100.0% | $2.0M | $0 | $0-100.0% | $5.0M+600.0% | -$1.0M+50.0% | -$2.0M |
| Net income (loss) | $350.0M-18.0% | $427.0M+114.6% | $199.0M+231.7% | $60.0M-64.3% | $168.0M+9.1% | $154.0M-85.3% | $1.05B+511.7% | $171.0M-13.2% | $197.0M-27.0% | $270.0M |
| Less: net income (loss) attributable to noncontrolling interests | $127.0M-0.8% | $128.0M+4.1% | $123.0M | — | — | — | $130.0M | — | — | — |
| Net income (loss) available to Genworth Financial, Inc.’s common stockholders | $223.0M-25.4% | $299.0M+293.4% | $76.0M+162.1% | $29.0M-78.8% | $137.0M+12.3% | $122.0M-86.7% | $916.0M+573.5% | $136.0M-14.5% | $159.0M-33.8% | $240.0M |
| Basic (in dollars per share) | $540000.00-21.7% | $690000.00+331.3% | $160000.00+166.7% | $60000.00-78.6% | $280000.00+12.0% | $250000.00-86.3% | $1820000.00+600.0% | $260000.00-18.8% | $320000.00-33.3% | $480000.00 |
| Diluted (in dollars per share) | $540000.00-20.6% | $680000.00+325.0% | $160000.00+166.7% | $60000.00-78.6% | $280000.00+16.7% | $240000.00-86.6% | $1790000.00+588.5% | $260000.00-16.1% | $310000.00-34.0% | $470000.00 |
| Basic (in shares) | 409.0M-5.7% | 433.9M-7.4% | 468.8M+1.8% | 460.5M-2.7% | 473.2M-3.9% | 492.3M-2.4% | 504.4M+0.1% | 503.8M-1.0% | 508.9M+0.1% | 508.3M |
| Diluted (in shares) | 414.0M-5.8% | 439.4M-7.5% | 474.9M+1.9% | 466.0M-2.5% | 478.1M-4.4% | 500.1M-2.1% | 510.9M+0.3% | 509.3M-0.9% | 514.1M-0.6% | 517.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.